Building on these foundational studies, our research aimed to further elucidate the therapeutic potential of NGR1 in DN by identifying and validating its drug targets, particularly focusing on inflammatory targets such as ITGB8. The gene discussed is ITGB8; the disease is liver dysplastic nodule.